Journal article
Tegaserod for the treatment of chronic constipation: A randomized, double-blind, placebo-controlled multinational study
MA Kamm, S Müller-Lissner, NJ Talley, J Tack, G Boeckxstaens, ON Minushkin, A Kalinin, J Dzieniszewski, P Haeck, F Fordham, S Hugot-Cournez, B Nault
American Journal of Gastroenterology | Published : 2005
Abstract
OBJECTIVES: Chronic constipation is a common, persistent disorder with limited effective treatment options. This study investigated the efficacy, safety, and tolerability of tegaserod in the treatment of chronic constipation. METHODS: After a 2-wk baseline period, patients were randomized to double-blind treatment of 12 wk with tegaserod (2 or 6 mg b.i.d.) or placebo. Response during weeks 1-4 (primary variable) was defined as an increase in complete spontaneous bowel movement (CSBM)/wk. Secondary variables included response during weeks 1-12, patient evaluation of individual symptoms, and global assessment of bowel habits and constipation. RESULTS: One thousand two hundred and sixty-four pa..
View full abstract